Erleada Improves Survival in Metastatic Castration-Sensitive Prostate Cancer, Phase 3 Trial Finds
News
Adding Janssen‘s androgen receptor inhibitor Erleada (apalutamide) to first-line androgen deprivation therapy (ADT) significantly extended survival and delayed disease progression or death in metastatic castration-sensitive prostate cancer patients included in a Phase 3 ... Read more